Bhaskar Raju, MD
Child & Adolescent Psychiatry · Orlando, FLNPI 1558397620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 612 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 26.6% of the total. Reporting peaked in 2023 at $3,361 and has fallen 68.2% since, to $1,069 in 2025. Among child & adolescent psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 612 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$884
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$850
- Alkermes, Inc.$664
- Ironshore Pharmaceuticals Inc.$605
- Tris Pharma Inc$567
- plus $5K from 26 others
Across 31 payments — averaging $3185.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$99K
What the payments were for
- Food & beverage$11,080100%
- Gifts$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- Quillivant$147
- ARISTADA INITIO$125
- VRAYLAR$101
How this compares
$11,082 in reported general payments places this provider in the 95th percentile of 206 child & adolescent psychiatry providers in Florida.
See all child & adolescent psychiatry providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 76 | $114,489 |
| CaplytaLumateperone Tosylate | 36 | $63,277 |
| RexultiBrexpiprazole | 45 | $63,040 |
| Invega SustennaPaliperidone Palmitate | 19 | $52,712 |
| TrintellixVortioxetine Hydrobromide | 44 | $25,135 |
| Aripiprazole | 144 | $15,384 |
| BelsomraSuvorexant | 27 | $11,714 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $11,111 |
| QuviviqDaridorexant Hcl | 16 | $7,715 |
| Quetiapine Fumarate | 454 | $7,077 |
| Duloxetine Hcl | 233 | $6,572 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 222 | $6,396 |
| Clonazepam | 807 | $6,261 |
| Lisdexamfetamine Dimesylate | 29 | $5,154 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 121 | $3,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,947 | $114,48976 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $850 | $63,27736 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $884 | $63,04045 claims |
| Johnson & JohnsonInvega Sustenna | $450 | $52,71219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $433 | $36,24770 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $17 | $7,71516 claims |
| Almatica Pharma LLCSertraline Hcl | $61 | $1,806235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 child & adolescent psychiatry providers in Florida.
Other child & adolescent psychiatry in Orlando
- Myrtho BranchOrlando$5K
- Craig KuninsGulfport$265K
- Elias SarkisGainesville$169K
- Jeffrey AlvaroSt Petersburg$87K
- Rosa Negron MunozLakeland$39K
- Sean HoranMiami$17K
- Rachel AgustinesLargo$16K
- Carlos BorgeSarasota$15K
- Justin SpoonerPonte Vedra Beach$12K
- Americo PadillaMiami$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.